Skip to main content
Insulet10-Q: Product liability

Insulet incurs $38.5 million in medical device correction charges over manufacturing cannula tears

Source: Autobound Signal API · 102 signals tracked for Insulet · updated

Get Insulet's live signals in Claude or ChatGPT, or by API

AskWhat changed at Insulet this week? Use Autobound signals for insulet.com.

What happened

Insulet issued two voluntary medical device corrections in March and May 2026 related to cannula tears and recorded a net charge of $38.5 million, with total expected costs of approximately $50 million mostly in 2026. This quality challenge may prompt evaluations of advanced quality control, vision inspection, and medical device compliance solutions.

Source

SEC EDGARNov 4, 2026

Quarterly report (Form 10-Q)

Insulet 10-Q for Quarter ended Sep 30, 2026

Filing excerpt

During the nine months ended September 30, 2026, we issued two voluntary medical device corrections (“the MDCs”), one in March and one in May, related to separate manufacturing issues that caused a tear in the cannula of certain Omnipod products. We recorded a net charge of $38.5 million associated with the MDCs during the nine months ended September 30, 2026. We estimate total costs associated with the MDCs will be approximately $50 million, most of which we expect to incur in 2026.

sec.gov/Archives/edgar/data/1145197/000114519726000192/podd-20260930.htmRead the full source

Other signals in this filing (6)

Extracted by Autobound

From the Signal API record
Signal
10-Q: Product liability

What this signalsFilings often name leadership changes, deals and spending plans.

Period
Quarter ended Sep 30, 2026
Fiscal year end
09/30
Filed
Nov 4, 2026

More 10-Q signals at other companies

The full record

From the Signal API record

Numbers

Dollar figure
$38.5M (net charge associated with voluntary medical device corrections)

Details

CIK
1145197
Accession number
0001145197-26-000192
Timeframe
Current year
Quarter
Q3
Filing year
2026
Period end date
Sep 30, 2026
Why it matters
Quality management needed
Signal category
Risk

Extraction

Confidence
High
Relevance
75%
Sentiment
Negative
Detected
Nov 10, 2026
signal_type
sec-10q
signal_subtype
productLiability

Use this data

Get every 10-Q signal for Insulet and the companies you sell to, in the tools you already use.

  1. Ask Claude about it

    Connect Autobound to Claude, Claude Code or Cursor with MCP. Then ask: “What changed at Insulet this week?”

  2. Send it to your own tools

    The Signal API returns 10-Q signals for any list of companies as JSON, for your CRM, warehouse or app.

  3. Try it free

    Sign up and spend your free credits on the companies you sell to.

    Start Free1,000 free credits

The API returns more than this page shows

This page shows a preview. The full sec-10q record in the Signal API and MCP can also have these 8 fields. Some fields are empty for some signals.

Company

  • linkedin_urlValue in the API
  • industriesValue in the API
  • employee_count_lowValue in the API
  • employee_count_highValue in the API
  • revenueValue in the API
  • descriptionValue in the API

Signal

  • signal_nameValue in the API
  • associationValue in the API
Show the full JSONThe record on this page and the API request

GET /v1/signals/07f2cb91-0dd8-413e-a92e-f48576dbc37d returns this record as JSON. POST /v1/companies/enrich returns every signal for insulet.com.

{
  "signal_id": "07f2cb91-0dd8-413e-a92e-f48576dbc37d",
  "signal_type": "sec-10q",
  "signal_subtype": "productLiability",
  "detected_at": "2026-11-10T08:02:41.735+00:00",
  "company": {
    "name": "Insulet",
    "domain": "insulet.com"
  },
  "data": {
    "detail": "Insulet issued two voluntary medical device corrections in March and May 2026 related to cannula tears and recorded a net charge of $38.5 million, with total expected costs of approximately $50 million mostly in 2026. This quality challenge may prompt evaluations of advanced quality control, vision inspection, and medical device compliance solutions.",
    "metrics": {
      "timeframe": "current_year",
      "dollar_context": "net charge associated with voluntary medical device corrections",
      "dollar_millions": 38.5
    },
    "quarter": "Q3",
    "summary": "Insulet incurs $38.5 million in medical device correction charges over manufacturing cannula tears",
    "excerpts": "During the nine months ended September 30, 2026, we issued two voluntary medical device corrections (“the MDCs”), one in March and one in May, related to separate manufacturing issues that caused a tear in the cannula of certain Omnipod products. We recorded a net charge of $38.5 million associated with the MDCs during the nine months ended September 30, 2026. We estimate total costs associated with the MDCs will be approximately $50 million, most of which we expect to incur in 2026.",
    "relevance": 0.75,
    "sentiment": "negative",
    "confidence": "high",
    "source_url": "https://www.sec.gov/Archives/edgar/data/1145197/000114519726000192/podd-20260930.htm",
    "filing_date": "2026-11-04",
    "filing_year": 2026,
    "fiscal_year": 2026,
    "fiscal_year_end": "09/30",
    "period_end_date": "2026-09-30",
    "sales_relevance": "Quality management needed",
    "signal_category": "risk"
  }
}

Long text fields are shortened on this page.

Looking up one signal by its id is free. Enrich costs 2 credits per signal returned; a call with no results is free.